Disrupting the interaction of BRD4 with Twist1 by using BET-specific inhibitors (such as JQ1) may be a novel approach to indirectly suppress Twist1 function and provide a potential new target for the treatment of basal-like breast cancer [65]. Here, TWIST1 is linked to breast cancer.